49 results about "Myeloid tissue" patented technology

The invention belongs to the technical field of biological genetic engineering, and relates to a high-risk myelodysplastic syndrome screening gene and a diagnostic kit thereof. The invention provides an application of detecting YTHDF2, METTL3 and NAT10 gene expression of bone marrow cells of high-risk MDS patients as a specific molecular marker for screening the high-risk myelodysplastic syndrome, and by detecting mRNA expression levels of the YTHDF2, METTL3 and NAT10 genes, the screening of the patients in the high-risk myelodysplastic syndrome is facilitated. Meanwhile, treatment and prognosis evaluation of patients with high-risk myelodysplastic syndromes can be better guided. Only the bone marrow fluid of the patient needs to be extracted and collected during bone marrow cytology examination of the patient, the patient compliance is good, the bone marrow fluid is selected from human bone marrow fluid mononuclear cells, the detection result is more accurate, and the method is suitable for clinical large-scale application.

The invention belongs to the technical field of medical image processing, and provides a bone marrow cell WSI region-of-interest automatic analysis positioning method and system, and the method comprises the steps: obtaining a full glass slide bone marrow aspiration smear image (WSI); a pyramid network is adopted to zoom the full-glass-slide bone marrow aspiration smear image, and a low-resolution image is generated; designing a general area condition prompt strategy by combining bone marrow cytology medical priori knowledge, and calling a language model to construct text description of a bone marrow microparticle area for the low-resolution image; using a visual language model to align the text and the low-resolution image, and then adopting a feature visualization technology and based on gradient weighted channel selection to generate a semantic response graph; the dispersion degree of a semantic response region in the semantic response graph is calculated, and segmentation prompt information is generated by adopting a region perception and strategy self-adaption mechanism; and inputting segmentation prompt information and the low-resolution image into an SAM model, generating an ROI mask image through reasoning, and completing positioning of the bone marrow cell WSI region of interest.

The present invention relates to methods and compositions for the treatment of BAF-related disorders such as acute myeloid leukemia.

The present invention belongs to the field of biological genetic engineering technology and relates to high-risk myelodysplastic syndrome screening genes and diagnostic kits. The present invention provides an application of detecting the expression of YTHDF2, METTL3, and NAT10 genes in bone marrow cells of high-risk MDS patients as a specific molecular marker for screening high-risk myelodysplastic syndrome. By detecting the expression levels of YTHDF2, METTL3, and NAT10 genes mRNA, it helps to screen patients with high-risk myelodysplastic syndrome and better guide the treatment and prognosis evaluation of patients with high-risk myelodysplastic syndrome. The present invention only needs to extract the patient's bone marrow fluid and collect it together when the patient undergoes bone marrow cytology examination. The patient compliance is good, and the material is taken from human bone marrow fluid mononuclear cells. The test results are more accurate and suitable for large-scale clinical application.

The present invention relates to a computer-implemented method for producing a trained model for detecting one or more defined cell types and / or cellular indicators, such as biomarkers or cellular abnormalities, in particular genomic aberrations, from single-cell images obtained from a sample of a body liquid, bone marrow, cytology smear or slide preparations, in particular a blood smear sample. It relates also to a computer-implemented method for detecting one or more defined cell types and / or cellular indicators, such as biomarkers or cellular abnormalities, in particular genomic aberrations, from single-cell images obtained from a sample of a body liquid, bone marrow or cytology smear, in particular a blood smear sample.

The invention discloses a staurosporine glucoside derivative as well as a preparation method and application thereof, and belongs to the field of medicine synthesis. C3-NHCH3 of staurosporine is subjected to glycosylation modification, and the staurosporine glycoside derivative shown in the formula (I) is prepared. The glycoside derivative prepared by the invention has a better inhibition effect on human acute myeloid leukemia cells THP-1, human bladder cancer cells 5637, human colon cancer cells HCT-116, human pancreatic cancer cells PATU8988T and human liver cancer cells HuH-7, and the compound 5 also has an excellent inhibition effect on human gastric cancer cells MKN-45. A candidate compound is provided for development of drugs for bladder cancer, colon cancer, pancreatic cancer, liver cancer, stomach cancer or acute myeloid leukemia.

This invention discloses a bone marrow cell paraffin block, its preparation method, and its application, belonging to the field of pathological detection technology. The preparation method includes the following steps: Red blood cell lysis: Bone marrow aspirate is taken, and a precipitate containing cells and sediment is separated. A red blood cell lysis agent is added to lyse the red blood cells, and a lysed precipitate containing unlysed cells and sediment is separated. Formation: The lysed precipitate is resuspended in formalin solution for fixation, the supernatant is removed, and the precipitate is resuspended in agar solution. The agar is cooled and solidified, and then fixed again in neutral formalin. Dehydration: The solidified agar block is dehydrated. Embedding: The dehydrated agar block is embedded in paraffin to form a paraffin block. The cell paraffin block prepared by this method can supplement the diagnosis when bone marrow smears or bone marrow biopsy samples are not ideally prepared.

The present application relates to the technical field of traditional Chinese medicine, in particular to a traditional Chinese medicine composition for reducing adverse reactions after radiotherapy and chemotherapy of tumor patients and a preparation method thereof, comprising the following components in parts by weight: Radix Bupleuri 6-9 parts, Radix Paeoniae Alba 6-9 parts, Rhizoma Atractylodis Macrocephalae 6-9 parts, Poria 6-9 parts, Angelica sinensis 6-9 parts, Zingiber officinale 3 parts, Radix Rehmanniae Recens 3-6 parts, Gardenia 3-6 parts, Radix Paeoniae Rubra 3-6 parts, Radix Paeoniae Alba 12-20 parts, Rhizoma Chuanxiong 6 parts, and Radix Glycyrrhizae 3-6 parts; the traditional Chinese medicine composition can improve the spirit and movement state of mice, and the weight and food intake of mice are obviously increased, the number of dead mice is significantly reduced, and the tumor volume and weight of mice are significantly reduced; the spleen and thymus indexes, the number of white blood cells, red blood cells and platelets in peripheral blood, and the hemoglobin content are all significantly increased; the number of bone marrow cells and the CD4 + T / CD8 + T cell ratio in peripheral blood are all significantly increased; when applied to clinical patients, the traditional Chinese medicine composition can reduce adverse reactions after radiotherapy and chemotherapy of tumor patients, and has a broad application prospect.

The invention discloses a bone marrow smear preparation method based on air source purging, system equipment and a medium, and relates to the technical field of medical examination and cell preparation, and the method comprises the following steps: obtaining and processing a bone marrow cell sample to form a cell suspension; applying the cell suspension to a glass slide, and performing directional treatment on the cell suspension in an air source purging manner; fixing and dyeing the bone marrow smear which is formed by blowing through an air source, so as to complete the smear preparation operation of the bone marrow smear. According to the method, smear quality fluctuation caused by sample state difference is remarkably reduced, a uniform basic suspension condition is provided for stable development of subsequent airflow purging, smear preparation consistency and reproducibility are optimized from the source, smear region distribution quality improvement and stable acquisition of morphological analysis results are achieved, and the method is suitable for large-scale popularization and application. The dyeing uniformity and the color development consistency are improved, and better effects are achieved in the aspects of cell resuspension uniformity, cell spreading consistency and film production process standardization.

The present disclosure generally relates to the treatment of subjects having myeloid cell dysfunction or at risk of developing myeloid cell dysfunction by administering a Membrane Spanning 4-Domains A6A (MS4A6A) inhibitor and / or a Membrane Spanning 4-Domains A64A (MS4A4A) inhibitor to the subject.

The application discloses a bone marrow morphology acute event identification early warning system and relates to the technical field of intelligent medical treatment, and the technical solution points are as follows: acquiring bone marrow cell image data, pre-processing, obtaining pre-processed image data; inputting the pre-processed image data into a trained AI model, and outputting a classification prediction result. The application can more accurately identify and classify bone marrow cells by applying a visual Transformer and a visual Mamba model, can identify different cell development stages, and can diagnose various blood diseases through an AI model standardized analysis process, reduce professional barriers in the field of bone marrow morphology, reduce absolute dependence on expert experience, and enable areas with insufficient medical conditions to also obtain high-quality preliminary diagnosis.

Methods of treating acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) are provided, as are compositions and combinations suitable for use in said methods.

The invention relates to the technical field of compounds, in particular to VHL derivatives and application thereof in preparation of SMARCA2 degradation agents. Specifically, the invention discloses a compound as shown in a chemical structural formula I, a tautomer, an enantiomer, a diastereoisomer and pharmaceutically acceptable salts, solvates or hydrates thereof. The compound or a pharmaceutical composition containing the compound can be used for preparing a PROTACS degradation agent aiming at an SMARCA2 target spot, and particularly preparing medicines for treating acute myeloid leukemia, myelodysplastic syndrome, uveal melanoma and the like. # imgabs0 #

The application discloses a kind of bone marrow cell few sample classification method, system and electronic equipment, method includes: obtaining bone marrow cell dataset, constructs few sample training set and test set establishes the multi-scale multi-modal few sample classification network model based on text multi-source generation selection;According to the few sample training set, the few sample classification network model is trained, and the trained bone marrow cell classification network model is obtained;The bone marrow cell image of test is input into the bone marrow cell classification network model, and the prediction class of bone marrow cell image is obtained, realizes the bone marrow cell image classification under the condition of few sample training.The present application selects histopathology pre-training model for bone marrow cell classification, and designs text multi-source generation selection module, standardizes the semantic description of each category of bone marrow cell, and further improves the few sample classification accuracy of bone marrow cell, which can be widely applied in the field of computer vision technology.

The invention provides a chimeric antigen receptor for treating acute myeloid leukemia, a cell, a nucleotide sequence of the cell, a recombinant expression vector and a pharmaceutical composition. The chimeric antigen receptor targets acute myelogenous leukemia tumor cells and stromal cells around the acute myelogenous leukemia tumor cells at the same time. The invention creates a novel double-targeting CAR structure, and provides a CAR-T cell which is used for treating acute myeloid leukemia and is double-targeted to CLL1 and CD146, and AML cells and stromal cells forming an AML microenvironment can be removed at the same time.

The invention relates to the crossing field of medical image processing and artificial intelligence technology, in particular to a bone marrow cell morphology artificial intelligence analysis method and system, and the method comprises the steps: obtaining a multi-view high-resolution image of a bone marrow smear and / or a peripheral blood smear under the oil immersion magnification, and carrying out the preprocessing; carrying out red blood cell coarse segmentation and fine classification through a cascade deep network, and identifying target-shaped, broken, teardrop-shaped and elliptical red blood cells; correcting broken red blood cell counting by adopting a fragment aggregation correction algorithm; and calculating an MCI value in combination with blood routine test data, and carrying out weighted fusion on the MCI value and the abnormal red blood cell proportion to generate a thalassemia screening comprehensive score. Therefore, the problems of low manual identification efficiency, insufficient abnormal red blood cell identification accuracy, large broken red blood cell counting deviation, difficulty in distinguishing multiple types of abnormal red blood cells, lack of organic combination with clinical diagnosis indexes and the like are solved, and the efficiency and accuracy of morphological analysis of bone marrow cells are improved; and a reliable basis is provided for diagnosis of diseases such as thalassemia.

The present invention relates to a computer-implemented method for producing a trained model for detecting one or more defined cell types and / or cellular indicators, such as biomarkers or cellular abnormalities, in particular genomic aberrations, from single-cell images obtained from a sample of a body liquid, bone marrow, cytology smear or slide preparations, in particular a blood smear sample. It relates also to a computer-implemented method for classifying a sample of a body liquid, bone marrow or cytology smear, in particular a blood smear sample, as indicative or non-indicative of one or more defined cell types and / or cellular indicators, such as biomarkers or cellular abnormalities, in particular genomic aberrations, from single-cell images obtained from the sample.

The invention relates to the technical field of medical image processing, in particular to a blood disease classification-oriented bone marrow cell multi-scale identification method, which comprises the following steps of: constructing and training a bone marrow cell identification model, and inputting an image to be identified into the trained bone marrow cell identification model to obtain an identification result; the bone marrow cell recognition model comprises a hierarchical feature extraction module, a feature enhancement module, a class center learning framework module and a multi-layer perceptron; compared with an existing model, the classification number and accuracy of cell classification are improved, preliminary diagnosis of hematologic tumor diseases can be achieved in an auxiliary mode, and the examination time is shortened.

Provided herein are antibodies that bind signal regulatory protein gamma (SIRPy), as well as SIRPα and / or SIRPβ1, and methods of using such antibodies (referred to as SIRP antibodies). In some embodiments, the SIRP antibodies are human monoclonal antibodies that bind human SIRPy as well as SIRPα and / or SIRPβ1. In some embodiments, the SIRP antibodies provided herein are useful for treating a disease or condition associated with overactivation and / or hyperproliferation of lymphocytes, myeloid cells, or a combination thereof, or a disease or condition associated with SIRPα, SIRPβ1 and / or SIRPy activity.

The application discloses a mouse bone marrow mesenchymal stem cell separation method, which comprises the following steps: S1, extracting mouse bone marrow cells; S2, performing flow staining, specifically comprising the following sub-steps: resuspending the mouse bone marrow cells by using Hanks buffer solution containing FBS to obtain a mouse bone marrow cell suspension, performing specific blocking treatment on the mouse bone marrow cell suspension, adding a fluorescently labeled monoclonal antibody to the mouse bone marrow cell suspension after centrifugation, washing and resuspension, and incubating to obtain the flow-stained mouse bone marrow cells; the fluorescently labeled monoclonal antibody comprises Anti-CD140a-APC, Anti-CD45-PE, Anti-Sca-1-FITC and Anti-Ter119-PE; S3, performing flow sorting on the flow-stained mouse bone marrow cells, sorting PE ‑ , FITC + , APC + cell groups by using a flow cytometer to obtain mouse bone marrow mesenchymal stem cells. The application can more efficiently and stably separate mouse bone marrow mesenchymal stem cells.

The present disclosure provides methods for making bone marrow hematopoietic progenitors lacking NF-κB p50 protein subunit (p50) and STAT6, or bone marrow hematopoietic progenitors lacking NF-κB p50 protein subunit and NF-κB p52 protein subunit. The progenitor cells are expanded, exposed to a myeloid cytokine, and provided intravenously to treat various malignancies. The infused cells have the potential to generate mature granulocytes, monocytes, macrophages, and dendritic cells. Methods for the genetically manipulation of a subject's hematopoietic progenitors during the expansion phase to reduce or eliminate expression of p50, p52, and / or STAT6 are also contemplated, and these progenitor cells may be combined with other therapeutic agents to maximize efficacy.

The invention provides a preparation method of an experimental animal bone marrow smear, and belongs to the technical field of hematological examination. According to the invention, a specific smear method is matched with homologous serum, so that the mechanical damage of bone marrow cells in the collection and smear preparation process can be obviously reduced, and the phenomena of excessive crushing and uneven distribution of the cells are effectively avoided, so that the high-quality bone marrow smear with complete cell morphology and clear background is prepared; therefore, the morphological observation effect and the reading success rate of the bone marrow cells are directly improved, reliable technical guarantee is provided for accurately evaluating the influence of the test substance on the hematopoietic function of the animal in non-clinical toxicity research, and the accuracy and repeatability of experimental results are enhanced.

The invention discloses a composition for inducing dental pulp cell reprogramming, the composition comprises a TGF-beta pathway inhibitor, an MEK inhibitor, a GSK3 inhibitor, coptisine, astragaloside and artemisinin, and the components have a synergistic effect to realize the dental pulp cell reprogramming; the invention further discloses a reprogramming culture medium composed of the composition and an alpha-MEM basic culture medium. The invention also discloses a reprogramming method for reprogramming the dental pulp cells by using the reprogramming culture medium, the method comprises the steps of dental pulp cell culture, cell inoculation, reprogramming culture and the like, and the induced pluripotent stem cells can be obtained by culturing the dental pulp cells in the reprogramming culture medium for 14 days. The composition disclosed by the invention is definite in component, the reprogramming efficiency of the dental pulp cells can be remarkably improved, and the reprogrammed induced pluripotent stem cells are good in dryness and high in hereditary stability, and can be widely applied to the cell reprogramming fields such as regenerative medicine, oral disease treatment and drug development.

This invention discloses a method for identifying bone marrow cells from microscopic images based on feature fusion, comprising: acquiring labeled microscopic images of bone marrow cells to construct a dataset, dividing it into a training set and a test set; performing data augmentation on the images in the training set to obtain an augmented training set; feeding the augmented training set into an improved Mask R-CNN network for training to obtain an optimal model; inputting the test set into the optimal model to obtain prediction information, including: the location bounding box, category, and segmentation mask information of each bone marrow cell; drawing this information onto the original image; and marking the predicted bone marrow cell category above the location bounding box, thereby completing the identification of bone marrow cells. This invention improves the generalization of bone marrow cell image recognition across various color styles.

This utility model relates to a semi-automatic bone marrow cell morphology slide washing instrument, comprising: a washing chamber with multiple slots for holding slides; and a robotic arm equipped with a washing head for driving the washing head to move. By holding the slides in the slots and using the robotic arm to drive the washing head, the water flow and angle can be controlled, reducing cell detachment. The closed washing chamber design allows the operator to have zero contact with the staining solution, improving operational safety. Multiple slides can be processed at a time, increasing washing efficiency.

The application discloses application of circular RNA hsa_circ_0012152 as a therapeutic target in preparation of a medicine for treating acute myelocytic leukemia of children.

The application provides a method for automatically segmenting white blood cells in bone marrow cells, comprising the following steps: S1, extracting obvious cells CellGray from an input bone marrow cell rgb image through a convolutional neural network; S2, binarizing the bone marrow cell image CellGray to obtain a white blood cell nucleus binary image; S3, performing an opening and closing operation on the white blood cell nucleus binary image in the aspect of image morphology to obtain WhiteCellMorph, and performing a watershed algorithm operation on WhiteCellMorph to obtain a white blood cell nucleus segmentation image Leukocytenucleus; S4, shielding corresponding numbers in the CellGray data obtained in step S1 by using the Leukocytenucleus obtained in step S3, and obtaining a white blood cell membrane Leukocytemembrane by using an Otsu method and an opening and closing operation in the aspect of image morphology; and S5, combining the data obtained in steps S3 and S4 to obtain a segmented complete white blood cell image, extracting an accurate position of the white blood cell, and generating a standard data set. The application can effectively improve the accuracy of overall positioning and segmentation of white blood cell images, and generate a data set, thereby facilitating the development of artificial intelligence for subsequent white blood cell type recognition.

This invention describes new methods for the mobilization of human cells such as hematopoietic stem cells in bone marrow, and the subsequent collection of such cells from the peripheral blood of deceased donors. These methods produce quantities of hematopoietic stem cells that can be used in a multitude of possible applications without harming the deceased donor or the recovery of the deceased donor's organs for solid organ transplantation. The methods involve the administration of one or more mobilizing agents to mobilize bone marrow cells into the peripheral blood cells followed by the collection of cells via apheresis.

The invention discloses humanized lactobacillus johnsonii MYR-117 and application thereof, the preservation number of the humanized lactobacillus johnsonii MYR-117 is GDMCC No: 65346, the humanized lactobacillus johnsonii MYR-117 is separated and identified from a faeces sample of a healthy person, and a mouse myelosuppression model is further combined to find that the lactobacillus johnsonii can resist myelosuppression induced by cyclophosphamide, so that the lactobacillus johnsonii MYR-117 can be used for resisting myelosuppression induced by cyclophosphamide; the levels of white blood cells, hemoglobin, platelets and red blood cells can be increased, bone marrow cell apoptosis is reduced, the thighbone marrow form is recovered, and the bone marrow hematopoietic capacity is Therefore, the compound can be used for preparing anti-myelosuppression drugs, leukocyte increasing drugs, erythrocyte increasing drugs, chemotherapy adjuvant therapy drugs and health-care products. Meanwhile, as the lactobacillus johnsonii is edible probiotics, the lactobacillus johnsonii can be used for preparing health-care food.